UCLA Researchers Develop Cellobiose Fuel to Supercharge Cancer-Fighting T Cells

New method aims to overcome metabolic challenges that limit immunotherapy's effectiveness against solid tumors.

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Researchers at UCLA have developed a novel approach to 'supercharge' T cells used in cancer immunotherapy by providing them with a unique fuel source - cellobiose - that cancer cells cannot easily access. This strategy aims to address a key limitation of immunotherapy against solid tumors, where tumor cells aggressively consume glucose, leaving T cells starved of energy and unable to effectively kill cancer cells. The preclinical study, published in Cell, demonstrates that cellobiose-fueled T cells are more resilient and maintain their anti-cancer activity for longer, offering a promising path to unlock the full potential of immunotherapy for a wider range of cancers.

Why it matters

Immunotherapy, particularly CAR-T cell therapy, has shown remarkable success in treating blood cancers, but its application to solid tumors has been hampered by the tumor microenvironment. Solid tumors create a metabolically challenging landscape for immune cells, as they aggressively consume glucose, leaving T cells starved of energy and unable to effectively kill cancer cells. This new approach aims to overcome this critical obstacle, potentially unlocking the full potential of immunotherapy for a wider range of cancers.

The details

The UCLA team focused on finding a way to feed T cells glucose without simultaneously fueling the tumor's growth. Their solution lies in cellobiose, a naturally occurring sugar found in plant fiber (cellulose). Crucially, human cells and tumors lack the necessary enzymes to break down cellobiose, meaning that when T cells are provided with cellobiose, they can metabolize it for energy, while the tumor cells are unable to utilize it, effectively creating a selective advantage for the immune cells. The researchers developed a method to deliver cellobiose specifically to the T cells, ensuring that the tumor doesn't benefit from the added sugar.

  • The findings were published in the journal Cell on February 25, 2026.

The players

Dr. Manish Butte

UCLA's E. Richard Stiehm Professor of Pediatric Allergy, Immunology and Rheumatology and a member of the UCLA Health Jonsson Comprehensive Cancer Center.

UCLA

A public research university located in Los Angeles, California, where the research was conducted.

Got photos? Submit your photos here. ›

What they’re saying

“A problem with solid tumors is that the immune system tries to fight the cancer, but the tumor cells deplete the key nutrient glucose from their environment. This leaves the T cells that show up to attack with not enough glucose to make cytokines and kill. The balance between tumor cells eating the glucose and the T cells not having enough glucose is a key reason why tumors spread and elude immune attack.”

— Dr. Manish Butte, UCLA's E. Richard Stiehm Professor of Pediatric Allergy, Immunology and Rheumatology

What’s next

The researchers are planning to conduct clinical trials to evaluate the safety and efficacy of this cellobiose-fueled T cell approach in treating solid tumors in cancer patients.

The takeaway

This novel strategy to provide a protected fuel source for T cells in the tumor microenvironment represents a significant step forward in addressing a major challenge in cancer immunotherapy. By overcoming the metabolic constraints that limit T cell function, this approach could potentially unlock the full potential of immunotherapy for a wider range of solid tumors that have proven resistant to conventional therapies.